Aireen


Aireen is a Czech startup specializing in AI-powered medical diagnostics, particularly in eye health. Their solutions are certified as CE MDR IIb medical devices, offering fast, autonomous, and precise screening for eye diseases such as diabetic retinopathy, age-related macular degeneration, and glaucoma. They aim to improve access to healthcare, reduce costs, and enable early detection of serious eye conditions.

Industries

artificial-intelligence
health-care
medical
medical-device

Nr. of Employees

small (1-50)

Aireen

Prague, Hlavni mesto Praha, Czech Republic, Europe


Products

Autonomous AI retinal screening platform (EU MDR IIb certified)

A medical-device-grade AI platform that analyses fundus images to screen for retinal diseases and deliver diagnostic results rapidly at point-of-care or via cloud service.


Services

Cloud-based retinal screening service (SaaS)

Subscription-based cloud service providing autonomous analysis of retinal photographs and diagnostic outputs for screening programs.

On-site screening deployment and integration

Implementation and workflow integration at point-of-care locations to enable non-specialist personnel to perform retinal screening and obtain diagnostic results.

Large-scale screening program support and payer integration

Support for deploying and scaling screening programs including collaboration with payers and healthcare organizations to enable reimbursement and program adoption.

Expertise Areas

  • Retinal image-based diagnostics
  • AI for medical imaging
  • Clinical validation of diagnostic devices
  • Medical device regulatory compliance (EU MDR, ISO 13485)
  • Show More (3)

Key Technologies

  • Deep learning for image analysis
  • Fundus / retinal photography
  • Cloud-based analytics and SaaS delivery
  • Automated disease grading algorithms
  • Show More (2)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.